{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:34:50Z","timestamp":1784219690529,"version":"3.55.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00535-022-01940-1","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T17:06:51Z","timestamp":1672420011000},"page":"299-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-7676","authenticated-orcid":false,"given":"Mina","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Kakinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","volume":"42","author":"P Cacoub","year":"1999","unstructured":"Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Arthritis Rheum. 1999;42:2204\u201312.","journal-title":"Arthritis Rheum"},{"key":"1940_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMra2033539","volume":"384","author":"P Cacoub","year":"2021","unstructured":"Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384:1038\u201352.","journal-title":"N Engl J Med"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","volume":"149","author":"F Negro","year":"2015","unstructured":"Negro F, Forton D, Crax\u00ec A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345\u201360.","journal-title":"Gastroenterology"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/v13112249","volume":"13","author":"C Mazzaro","year":"2021","unstructured":"Mazzaro C, Quartuccio L, Adinolfi LE, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 2021;13:2249.","journal-title":"Viruses"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11904-019-00466-1","volume":"16","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Salameh S, Butt AA. Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection. Curr HIV\/AIDS Rep. 2019;16:389\u201394.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"1940_CR7","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608\u201317.","journal-title":"N Engl J Med"},{"key":"1940_CR8","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMc1601160","volume":"374","author":"GR Foster","year":"2016","unstructured":"Foster GR, Mangia A, Sulkowski M. Sofosbuvir and velpatasvir for patients with HCV infection. N Engl J Med. 2016;374:1687\u20138.","journal-title":"N Engl J Med"},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332.","journal-title":"J Gastroenterol"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537\u201345.","journal-title":"Lancet"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","volume":"51","author":"G Suda","year":"2016","unstructured":"Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;51:733\u201340.","journal-title":"J Gastroenterol"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jhep.2020.11.005","volume":"74","author":"B Aqel","year":"2021","unstructured":"Aqel B, Wijarnpreecha K, Pungpapong S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. J Hepatol. 2021;74:873\u201380.","journal-title":"J Hepatol"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina Y, Tsuchiya K, Nishimura T, et al. \u03b1-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253\u201362.","journal-title":"Hepatology"},{"issue":"50","key":"1940_CR14","first-page":"775","volume":"2020","author":"Y Asahina","year":"2019","unstructured":"Asahina Y, Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH Guidelines for the Management of Hepatitis C Virus Infection. Update; protective effect of antiviral therapy against Hepatocarcinogenesis. Hepatol Res. 2019;2020(50):775\u201390.","journal-title":"Hepatol Res"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","volume":"156","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology. 2019;156:446-460.e2.","journal-title":"Gastroenterology"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","volume":"67","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025\u201334.","journal-title":"Gut"},{"key":"1940_CR17","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","volume":"66","author":"M Ramos-Casals","year":"2017","unstructured":"Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66:1282\u201399.","journal-title":"J Hepatol"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1002\/hep.510260711","volume":"26","author":"MJ Alter","year":"1997","unstructured":"Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:S62\u20135.","journal-title":"Hepatology"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJM199212313272703","volume":"327","author":"LB Seeff","year":"1992","unstructured":"Seeff LB, Buskellbales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A-hepatitis non-B-hepatitis. New Engl J Med. 1992;327:1906\u201311.","journal-title":"New Engl J Med"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","volume":"332","author":"MJ Tong","year":"1995","unstructured":"Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463\u20136.","journal-title":"N Engl J Med"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513\u201320.","journal-title":"Hepatology"},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825\u201332.","journal-title":"Lancet"},{"key":"1940_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cncr.10662","volume":"95","author":"H Hamada","year":"2002","unstructured":"Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95:331\u20139.","journal-title":"Cancer"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.23691","volume":"52","author":"Y Asahina","year":"2010","unstructured":"Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518\u201327.","journal-title":"Hepatology"},{"key":"1940_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/2053","volume":"4","author":"K Moriya","year":"1998","unstructured":"Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065\u20137.","journal-title":"Nat Med"},{"key":"1940_CR26","first-page":"4365","volume":"61","author":"K Moriya","year":"2001","unstructured":"Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001;61:4365\u201370.","journal-title":"Cancer Res"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","volume":"77","author":"J Leslie","year":"2022","unstructured":"Leslie J, Geh D, Elsharkawy AM, et al. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. J Hepatol. 2022;77:219\u201336.","journal-title":"J Hepatol"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/apt.14802","volume":"48","author":"F Wandrer","year":"2018","unstructured":"Wandrer F, Han B, Liebig S, et al. Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2018;48:270\u201380.","journal-title":"Aliment Pharmacol Ther"},{"key":"1940_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ncb2784","volume":"15","author":"JC Acosta","year":"2013","unstructured":"Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15:978\u201390.","journal-title":"Nat Cell Biol"},{"key":"1940_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature10600","volume":"479","author":"DJ Baker","year":"2011","unstructured":"Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479:232\u20136.","journal-title":"Nature"},{"issue":"Suppl 1","key":"1940_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4\u201313.","journal-title":"Hepatology"},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jceh.2014.02.155","volume":"4","author":"P Kar","year":"2014","unstructured":"Kar P. Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol. 2014;4:S34-42.","journal-title":"J Clin Exp Hepatol"},{"key":"1940_CR33","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557\u201376.","journal-title":"Gastroenterology"},{"key":"1940_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hepr.12393","volume":"45","author":"N Hiramatsu","year":"2015","unstructured":"Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152\u201361.","journal-title":"Hepatol Res"},{"key":"1940_CR35","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s00535-020-01731-6","volume":"55","author":"D Miki","year":"2020","unstructured":"Miki D, Akita T, Kurisu A, et al. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. J Gastroenterol. 2020;55:1162\u201370.","journal-title":"J Gastroenterol"},{"key":"1940_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121\u20134.","journal-title":"Science"},{"key":"1940_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","volume":"14","author":"WE Naugler","year":"2008","unstructured":"Naugler WE, Karin M. The wolf in sheep\u2019s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109\u201319.","journal-title":"Trends Mol Med"},{"key":"1940_CR38","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ijc.24720","volume":"125","author":"H Nakagawa","year":"2009","unstructured":"Nakagawa H, Maeda S, Yoshida H, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer. 2009;125:2264\u20139.","journal-title":"Int J Cancer"},{"key":"1940_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1053\/j.gastro.2010.12.027","volume":"140","author":"E Villa","year":"2011","unstructured":"Villa E, Karampatou A, Camm\u00e0 C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011;140:818\u201329.","journal-title":"Gastroenterology"},{"key":"1940_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep.1840190407","volume":"19","author":"JM Pawlotsky","year":"1994","unstructured":"Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19:841\u20138.","journal-title":"Hepatology"},{"key":"1940_CR41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.7326\/0003-4819-123-8-199510150-00008","volume":"123","author":"SC Gumber","year":"1995","unstructured":"Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995;123:615\u201320.","journal-title":"Ann Intern Med"},{"key":"1940_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2362.1993.tb00782.x","volume":"23","author":"C Ferri","year":"1993","unstructured":"Ferri C, La Civita L, Longombardo G, et al. Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest. 1993;23:399\u2013405.","journal-title":"Eur J Clin Invest"},{"key":"1940_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.678546","volume":"12","author":"H Roguljic","year":"2021","unstructured":"Roguljic H, Nincevic V, Bojanic K, et al. Impact of DAA treatment on cardiovascular disease risk in chronic HCV infection: an update. Front Pharmacol. 2021;12: 678546.","journal-title":"Front Pharmacol"},{"key":"1940_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.14218\/JCTH.2017.00021","volume":"5","author":"A Babiker","year":"2017","unstructured":"Babiker A, Jeudy J, Kligerman S, et al. Risk of cardiovascular disease due to chronic hepatitis C infection: a review. J Clin Transl Hepatol. 2017;5:343\u201362.","journal-title":"J Clin Transl Hepatol"},{"key":"1940_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","volume":"5","author":"R Zampino","year":"2013","unstructured":"Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528\u201340.","journal-title":"World J Hepatol"},{"key":"1940_CR46","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/ncomms5982","volume":"5","author":"M Tanaka","year":"2014","unstructured":"Tanaka M, Ikeda K, Suganami T, et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun. 2014;5:4982.","journal-title":"Nat Commun"},{"key":"1940_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1507\/endocrj.EJ19-0417","volume":"67","author":"M Tanaka","year":"2020","unstructured":"Tanaka M. Molecular mechanism of obesity-induced adipose tissue inflammation; the role of Mincle in adipose tissue fibrosis and ectopic lipid accumulation. Endocr J. 2020;67:107\u201311.","journal-title":"Endocr J"},{"key":"1940_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep.26017","volume":"57","author":"S Nitta","year":"2013","unstructured":"Nitta S, Sakamoto N, Nakagawa M, et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology. 2013;57:46\u201358.","journal-title":"Hepatology"},{"key":"1940_CR49","doi-asserted-by":"publisher","first-page":"15669","DOI":"10.1073\/pnas.202608199","volume":"99","author":"AI Su","year":"2002","unstructured":"Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA. 2002;99:15669\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1940_CR50","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1073\/pnas.0409834102","volume":"102","author":"SB Kapadia","year":"2005","unstructured":"Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005;102:2561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1940_CR51","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jhep.2016.06.011","volume":"65","author":"P Cacoub","year":"2016","unstructured":"Cacoub P, Desbois AC, Isnard-Bagnis C, et al. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65:S82-94.","journal-title":"J Hepatol"},{"key":"1940_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","volume":"296","author":"LE Adinolfi","year":"2020","unstructured":"Adinolfi LE, Petta S, Fracanzani AL, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study. Atherosclerosis. 2020;296:40\u20137.","journal-title":"Atherosclerosis"},{"key":"1940_CR53","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/j.gastro.2019.02.009","volume":"156","author":"P Cacoub","year":"2019","unstructured":"Cacoub P, Hepatitis C. Virus infection, a new modifiable cardiovascular risk factor. Gastroenterology. 2019;156:862\u20134.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"1940_CR54","first-page":"SII20","volume":"69","author":"C Ferri","year":"2002","unstructured":"Ferri C, Zignego AL, Giuggioli D, et al. HCV and cryoglobulinemic vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):SII20\u20133.","journal-title":"Cleve Clin J Med"},{"key":"1940_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102923","volume":"21","author":"L Gragnani","year":"2022","unstructured":"Gragnani L, Lorini S, Marri S, et al. Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. Autoimmun Rev. 2022;21: 102923.","journal-title":"Autoimmun Rev"},{"key":"1940_CR56","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599\u2013608.","journal-title":"Gastroenterology"},{"key":"1940_CR57","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","volume":"125","author":"JP Gisbert","year":"2003","unstructured":"Gisbert JP, Garc\u00eda-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin\u2019s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723\u201332.","journal-title":"Gastroenterology"},{"key":"1940_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.29364","volume":"67","author":"M Persico","year":"2018","unstructured":"Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma. Hepatology. 2018;67:48\u201355.","journal-title":"Hepatology"},{"key":"1940_CR59","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128:2527\u201332.","journal-title":"Blood"},{"key":"1940_CR60","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jvh.12518","volume":"23","author":"J Peveling-Oberhag","year":"2016","unstructured":"Peveling-Oberhag J, Arcaini L, Bankov K, et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23:536\u201344.","journal-title":"J Viral Hepat"},{"key":"1940_CR61","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575\u20138.","journal-title":"N Engl J Med"},{"key":"1940_CR62","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Inter Med. 1999;131:174.","journal-title":"Ann Inter Med"},{"key":"1940_CR63","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.2003.030353","volume":"53","author":"H Yoshida","year":"2004","unstructured":"Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425\u201330.","journal-title":"Gut"},{"key":"1940_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22694","volume":"49","author":"SL George","year":"2009","unstructured":"George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729\u201338.","journal-title":"Hepatology"},{"key":"1940_CR65","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0168-8278(99)80196-2","volume":"30","author":"T Okanoue","year":"1999","unstructured":"Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients Viral Hepatitis Therapy Study Group. J Hepatol. 1999;30:653\u20139.","journal-title":"J Hepatol"},{"key":"1940_CR66","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","volume":"346","author":"S Nishiguchi","year":"1995","unstructured":"Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051\u20135.","journal-title":"Lancet"},{"key":"1940_CR67","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C Virus infection and the development of hepatocellular carcinoma a meta-analysis of observational studies. Ann Intern Med. 2013;158:329.","journal-title":"Ann Intern Med"},{"key":"1940_CR68","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Mari\u00f1o Z, Perell\u00f3 C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719\u201326.","journal-title":"J Hepatol"},{"key":"1940_CR69","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1172\/JCI75938","volume":"124","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014;124:3352\u201363.","journal-title":"J Clin Invest"},{"key":"1940_CR70","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","volume":"154","author":"JD Debes","year":"2018","unstructured":"Debes JD, van Tilborg M, Groothuismink ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515-517.e3.","journal-title":"Gastroenterology"},{"key":"1940_CR71","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/hep.27971","volume":"62","author":"AF Carlin","year":"2015","unstructured":"Carlin AF, Aristizabal P, Song Q, et al. Temporal dynamics of inflammatory cytokines\/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology. 2015;62:1047\u201358.","journal-title":"Hepatology"},{"key":"1940_CR72","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","volume":"68","author":"F Faillaci","year":"2018","unstructured":"Faillaci F, Marzi L, Critelli R, et al. Liver angiopoietin-2 is a key predictor of De Novo or recurrent hepatocellular cancer after hepatitis C Virus direct-acting antivirals. Hepatology. 2018;68:1010\u201324.","journal-title":"Hepatology"},{"issue":"1","key":"1940_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/ijms20010049","volume":"20","author":"R Villani","year":"2018","unstructured":"Villani R, Vendemiale G, Serviddio G. Molecular mechanisms involved in HCC recurrence after direct-acting antiviral therapy. Int J Mol Sci. 2018;20(1):49.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1940_CR74","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Mari\u00f1o Z, Perell\u00f3 C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65(4):719\u201326.","journal-title":"J Hepatol"},{"key":"1940_CR75","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.14427","volume":"47","author":"F Mettke","year":"2018","unstructured":"Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2018;47:516\u201325.","journal-title":"Aliment Pharmacol Ther"},{"key":"1940_CR76","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933\u20139.","journal-title":"J Hepatol"},{"key":"1940_CR77","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","volume":"157","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C Virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157:1253-1263.e2.","journal-title":"Gastroenterology"},{"issue":"6","key":"1940_CR78","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019;156(6):1683-1692.e1.","journal-title":"Gastroenterology"},{"key":"1940_CR79","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/liv.13357","volume":"37","author":"G Cabibbo","year":"2017","unstructured":"Cabibbo G, Petta S, Barb\u00e0ra M, et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 2017;37:1157\u201366.","journal-title":"Liver Int"},{"key":"1940_CR80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265\u201373.","journal-title":"J Hepatol"},{"issue":"3","key":"1940_CR81","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","volume":"71","author":"V Sapena","year":"2021","unstructured":"Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2021;71(3):593\u2013604.","journal-title":"Gut"},{"key":"1940_CR82","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00535-020-01747-y","volume":"56","author":"H Ochi","year":"2021","unstructured":"Ochi H, Hiraoka A, Hirooka M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol. 2021;56:90\u2013100.","journal-title":"J Gastroenterol"},{"key":"1940_CR83","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/hepr.13709","volume":"51","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Shinkawa H, Tamori A, et al. Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2021;51:1102\u201314.","journal-title":"Hepatol Res"},{"key":"1940_CR84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00535-021-01837-5","volume":"57","author":"Y Seko","year":"2022","unstructured":"Seko Y, Moriguchi M, Takahashi A, et al. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol. 2022;57:90\u20138.","journal-title":"J Gastroenterol"},{"key":"1940_CR85","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","volume":"156","author":"AA Butt","year":"2019","unstructured":"Butt AA, Yan P, Shuaib A, et al. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019;156:987-996.e8.","journal-title":"Gastroenterology"},{"key":"1940_CR86","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553\u201361.","journal-title":"Gut"},{"key":"1940_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","volume":"69","author":"S Petta","year":"2018","unstructured":"Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018;69:18\u201324.","journal-title":"J Hepatol"},{"key":"1940_CR88","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/dom.14168","volume":"22","author":"LE Adinolfi","year":"2020","unstructured":"Adinolfi LE, Petta S, Fracanzani AL, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study. Diabetes Obes Metab. 2020;22:2408\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"1940_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163644","volume":"11","author":"S Hashimoto","year":"2016","unstructured":"Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during Hepatitis C interferon-free treatment. PLoS\u00a0One. 2016;11: e0163644.","journal-title":"PLoS\u00a0One"},{"key":"1940_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","volume":"63","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337\u201345.","journal-title":"J Hepatol"},{"key":"1940_CR91","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","volume":"1","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1940_CR92","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jhep.2021.05.028","volume":"75","author":"NZ Janjua","year":"2021","unstructured":"Janjua NZ, Wong S, Abdia Y, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol. 2021;75:1049\u201357.","journal-title":"J Hepatol"},{"key":"1940_CR93","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","volume":"73","author":"V Calvaruso","year":"2020","unstructured":"Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020;73:1548\u201356.","journal-title":"J Hepatol"},{"key":"1940_CR94","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.29811","volume":"68","author":"LI Backus","year":"2018","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827\u201338.","journal-title":"Hepatology"},{"key":"1940_CR95","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hep.29408","volume":"69","author":"LI Backus","year":"2019","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2019;69:487\u201397.","journal-title":"Hepatology"},{"key":"1940_CR96","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453\u201364.","journal-title":"Lancet"},{"key":"1940_CR97","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","volume":"74","author":"LAP Krassenburg","year":"2021","unstructured":"Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053\u201363.","journal-title":"J Hepatol"},{"key":"1940_CR98","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","volume":"76","author":"R D'Ambrosio","year":"2022","unstructured":"D\u2019Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2022;76:302\u201310.","journal-title":"J Hepatol"},{"key":"1940_CR99","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/TP.0000000000001633","volume":"101","author":"C Vinaixa","year":"2017","unstructured":"Vinaixa C, Strasser SI, Berenguer M. Disease reversibility in patients with post-hepatitis C cirrhosis: is the point of no return the same before and after liver transplantation? A Review. Transplantation. 2017;101:916\u201323.","journal-title":"Transplantation"},{"key":"1940_CR100","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","volume":"160","author":"DC Rockey","year":"2021","unstructured":"Rockey DC, Friedman SL. Fibrosis regression after eradication of hepatitis C Virus: from bench to bedside. Gastroenterology. 2021;160:1502-1520.e1.","journal-title":"Gastroenterology"},{"key":"1940_CR101","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/hepr.13794","volume":"52","author":"S Kaneko","year":"2022","unstructured":"Kaneko S, Kurosaki M, Kurisu A, et al. Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: markov chain model analysis. Hepatol Res. 2022;52:665\u201376.","journal-title":"Hepatol Res"},{"key":"1940_CR102","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/hep.23528","volume":"51","author":"S Bruno","year":"2010","unstructured":"Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis A 12-year prospective follow-up study. Hepatology. 2010;51:2069\u201376.","journal-title":"Hepatology"},{"key":"1940_CR103","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692\u20139.","journal-title":"J Hepatol"},{"key":"1940_CR104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/hepr.13739","volume":"52","author":"M Atsukawa","year":"2022","unstructured":"Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235\u201346.","journal-title":"Hepatol Res"},{"key":"1940_CR105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1055\/s-0035-1550057","volume":"35","author":"P Ramachandran","year":"2015","unstructured":"Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis. 2015;35:119\u201331.","journal-title":"Semin Liver Dis"},{"key":"1940_CR106","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nbt1396","volume":"26","author":"Y Sato","year":"2008","unstructured":"Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26:431\u201342.","journal-title":"Nat Biotechnol"},{"key":"1940_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13861","author":"R Katoh","year":"2022","unstructured":"Katoh R, Maekawa S, Osawa L, et al. Significance of serum IP-10\/CXCL10 measurement in predicting post-daa treatment liver function in patients WITH HCV-decompensated liver cirrhosis. Hepatol Res. 2022. https:\/\/doi.org\/10.1111\/hepr.13861.","journal-title":"Hepatol Res"},{"key":"1940_CR108","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2017.10.012","volume":"68","author":"H Nagata","year":"2018","unstructured":"Nagata H, Nakagawa M, Asahina Y. Reply to: \"imaging asis of AFP and WFA. J Hepatol. 2018;68:607\u20138.","journal-title":"J Hepatol"},{"key":"1940_CR109","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00535-020-01715-6","volume":"55","author":"M Nakagawa","year":"2020","unstructured":"Nakagawa M, Nawa N, Takeichi E, et al. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol. 2020;55:990\u20139.","journal-title":"J Gastroenterol"},{"key":"1940_CR110","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/srep01065","volume":"3","author":"A Kuno","year":"2013","unstructured":"Kuno A, Ikehara Y, Tanaka Y, et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.","journal-title":"Sci Rep"},{"key":"1940_CR111","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/emboj\/17.6.1606","volume":"17","author":"T Sasaki","year":"1998","unstructured":"Sasaki T, Brakebusch C, Engel J, et al. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998;17:1606\u201313.","journal-title":"EMBO J"},{"key":"1940_CR112","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","volume":"230","author":"NC Henderson","year":"2009","unstructured":"Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160\u201371.","journal-title":"Immunol Rev"},{"key":"1940_CR113","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"UC Sharma","year":"2004","unstructured":"Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121\u20138.","journal-title":"Circulation"},{"key":"1940_CR114","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2016.06.027","volume":"251","author":"T Sugiura","year":"2016","unstructured":"Sugiura T, Dohi Y, Takase H, et al. Serum levels of Mac-2 binding protein increase with cardiovascular risk and reflect silent atherosclerosis. Atherosclerosis. 2016;251:192\u20136.","journal-title":"Atherosclerosis"},{"key":"1940_CR115","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.numecd.2019.08.008","volume":"29","author":"T Sugiura","year":"2019","unstructured":"Sugiura T, Dohi Y, Takase H, et al. Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: a prospective 3-year observational study. Nutr Metab Cardiovasc Dis. 2019;29:1337\u201344.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1940_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258589","volume":"16","author":"PS Wu","year":"2021","unstructured":"Wu PS, Hsieh YC, Lee KC, et al. Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. PLoS\u00a0One. 2021;16: e0258589.","journal-title":"PLoS\u00a0One"},{"key":"1940_CR117","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.30230","volume":"69","author":"AS Allegretti","year":"2019","unstructured":"Allegretti AS, Vela Parada X, Ortiz GA, et al. Serum angiopoietin-2 predicts mortality and kidney outcomes in decompensated cirrhosis. Hepatology. 2019;69:729\u201341.","journal-title":"Hepatology"},{"key":"1940_CR118","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/hepr.13490","volume":"50","author":"N Kawagishi","year":"2020","unstructured":"Kawagishi N, Suda G, Kimura M, et al. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 2020;50:671\u201381.","journal-title":"Hepatol Res"},{"key":"1940_CR119","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.1038\/s41598-021-88632-7","volume":"11","author":"N Kawagishi","year":"2021","unstructured":"Kawagishi N, Suda G, Kimura M, et al. Baseline elevated serum Angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep. 2021;11:9207.","journal-title":"Sci Rep"},{"key":"1940_CR120","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.7150\/jca.56436","volume":"12","author":"J Ao","year":"2021","unstructured":"Ao J, Chiba T, Kanzaki H, et al. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer. 2021;12:2694\u2013701.","journal-title":"J Cancer"},{"key":"1940_CR121","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1073\/pnas.1714446115","volume":"115","author":"T Souma","year":"2018","unstructured":"Souma T, Thomson BR, Heinen S, et al. Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proc Natl Acad Sci USA. 2018;115:1298\u2013303.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1940_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070459","volume":"8","author":"AV Benest","year":"2013","unstructured":"Benest AV, Kruse K, Savant S, et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS\u00a0One. 2013;8: e70459.","journal-title":"PLoS\u00a0One"},{"key":"1940_CR123","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcp.21229","volume":"214","author":"W Goettsch","year":"2008","unstructured":"Goettsch W, Gryczka C, Korff T, et al. Flow-dependent regulation of angiopoietin-2. J Cell Physiol. 2008;214:491\u2013503.","journal-title":"J Cell Physiol"},{"issue":"11","key":"1940_CR124","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/hepr.13823","volume":"52","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Matsuura K, Nagura Y, et al. Serum angiopoietin-2 levels predict regression of Mac-2 binding protein glycosylation isomer-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatol Res. 2022;52(11):919\u201327.","journal-title":"Hepatol Res"}],"updated-by":[{"DOI":"10.1007\/s00535-023-01961-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01940-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:07:22Z","timestamp":1680012442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01940-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01940-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00535-023-01961-4","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00535-023-01961-4","URL":"https:\/\/doi.org\/10.1007\/s00535-023-01961-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MN is an associate editor of the journal of gastroenterology. YA belongs to a donation-funded department funded by Gilead Sciences, AbbVie GK, Toray Industries, and Fujirebio Inc. SK belongs to a donation-funded department funded by Gilead Sciences, AbbVie GK, Toray Industries, and Fujirebio until May 2020. RO received a donation from Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co. Ltd and Mochida Pharmaceutical Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}